Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

NCT00513604 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

158

Enrollment

NIH

Sponsor class

Conditions

Melanoma
Malignant Melanoma
Melanoma, Experimental
Experimental Melanomas

Interventions

BIOLOGICAL: aldesleukin
BIOLOGICAL: therapeutic autologous lymphocytes
DRUG: Cyclophosphamide
DRUG: Fludarabine phosphate
RADIATION: Total body irradiation

Sponsor

National Cancer Institute (NCI)